Get the Stockscreener App
160.63
0.50%
0.80
After Hours:
160.63
Biogen Inc stock is traded at $160.63, with a volume of 1.07M.
It is up +0.50% in the last 24 hours and down -12.45% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$159.83
Open:
$160.72
24h Volume:
1.07M
Relative Volume:
0.84
Market Cap:
$23.41B
Revenue:
$9.61B
Net Income/Loss:
$1.62B
P/E Ratio:
8.7441
EPS:
18.37
Net Cash Flow:
$1.77B
1W Performance:
+1.73%
1M Performance:
-12.45%
6M Performance:
-25.08%
1Y Performance:
-30.78%
1-Day Range:
$158.44
$161.67
1-Week Range:
$156.09
$161.67
52-Week Range:
$153.62
$268.30
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
160.63 | 23.41B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
795.35 | 755.90B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
106.80 | 474.49B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
155.01 | 353.35B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
182.93 | 323.26B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
101.64 | 257.11B | 63.17B | 12.15B | 14.84B | 4.77 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 18,905 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Healthcare of Ontario Pension Plan Trust Fund - MarketBeat
Suvretta Capital Management LLC Makes New $5.81 Million Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Glenmede Trust Co. NA Acquires 66,583 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Bank of Montreal Can Has $42.81 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Antisense & RNAi Therapeutics Global Market Report 2024 To 2033 | - openPR
Oligonucleotide Delivery System Market Top PlayersBiogen, - openPR
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink? - MSN
Biogen Inc. (NASDAQ:BIIB) Shares Bought by Bridgewater Associates LP - MarketBeat
Why Biogen Inc. (BIIB) is One of the Cheapest Stocks to Buy on Robinhood? - Insider Monkey
BIIB (Biogen) Change In Receivables : $242 Mil (TTM As of Sep. 2024) - GuruFocus.com
"LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea - japancorp.net
"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea - StreetInsider.com
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Is Biogen Inc.'s (NASDAQ:BIIB) Recent Price Movement Underpinned By Its Weak Fundamentals? - Simply Wall St
January 2025 Options Now Available For Biogen (BIIB) - Nasdaq
Why Is Biogen Inc. (BIIB) Among the Worst Performing Healthcare Stocks in 2024? - Insider Monkey
Clark Estates Inc. NY Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - AOL
Smart Money Is Betting Big In BIIB Options - Benzinga
Eisai and Biogen Japan collaborate to lead dementia genomics R&D with NCNP in Japan - BSA bureau
These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over - The Motley Fool
Daiwa Securities Group Inc. Raises Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Swedbank AB Has $35.86 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan - japancorp.net
Biogen: Jefferies confirms its target as it awaits Ocrevus - Marketscreener.com
Bedell Frazier Investment Counselling LLC Buys 17,628 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Antisense & RNAi Therapeutics Market May See a Big Move | Isarna - openPR
Are Wall Street Analysts Predicting Biogen Stock Will Climb Or Sink? - Barchart
Charles Schwab Investment Management Inc. Buys 12,319 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Holdings Boosted by Massachusetts Financial Services Co. MA - MarketBeat
Notable analyst calls this week: Roku, Nvidia and Biogen among top picks - MSN
Notable analyst calls this week: Roku, Nvidia and Biogen among top picks (NASDAQ:ROKU) - Seeking Alpha
B. Metzler seel. Sohn & Co. Holding AG Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Natixis Advisors LLC Decreases Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Goldman Sachs: Biogen Inc. (BIIB) Is A Top Growth Investor Stock - Insider Monkey
BIIB (Biogen) 3-Year FCF Growth Rate : -28.10% (As of Sep. 2024) - GuruFocus.com
Biogen price target lowered to $207 from $251 at Mizuho - Yahoo Finance
Biogen Inc. (NASDAQ:BIIB) Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
Mutual of America Capital Management LLC Has $4.03 Million Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Monoclonal Antibody Therapeutics Market Is Booming Worldwide - openPR
Biogen Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Biogen (NASDAQ:BIIB) Given New $207.00 Price Target at Mizuho - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Stake Lowered by Primecap Management Co. CA - MarketBeat
Petri Dish: Kronos Bio seeks merger; Former Biogen R&D head joins investment firm - The Business Journals
BIIB (Biogen) Predictability Rank - GuruFocus.com
Biogen (WBO:BIIB) Profitability Rank : 7 (As of Sep. 2024) - GuruFocus.com
Biogen Unusual Options Activity For November 20 - Benzinga
ANCA Vasculitis Pipeline Trends 2024: Clinical Trials, - openPR
Biogen ‘welcomes’ EC decision to revoke CMAs for generic versions of Tecfidera - MSN
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):